Literature DB >> 34116198

Infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use.

Madelyn H Labella1, Rina D Eiden2, Alexandra R Tabachnick3, Tabitha Sellers3, Mary Dozier3.   

Abstract

BACKGROUND: Prenatal opioid exposure has been linked to adverse birth outcomes and delays in infant development. Existing literature is limited by a simple group-differences approach as well as inadequate controls for sociodemographic factors and polysubstance exposure co-occurring with prenatal opioid use.
METHOD: The current study assessed cumulative opioid exposure (duration of prescribed and illicit opioid use) as a predictor of infant birth outcomes and mother-reported developmental status at three and six months of age, controlling for polysubstance exposure. Participants were predominantly low-income pregnant and peripartum women, oversampled for mothers receiving medication-assisted treatment (MAT) for opioid use disorder. Prenatal opioid and non-opioid substance use were reported by mothers using a Timeline Follow-Back Interview completed during the third trimester and updated postnatally (infant age six months).
RESULTS: Developmental scores were in the normal range. However, total opioid exposure was positively related to premature birth and inversely related to mother-reported developmental status in specific domains. Associations with three-month fine motor skills and six-month communication skills were robust to controls for polysubstance exposure and sociodemographic covariates.
CONCLUSIONS: Results suggest unique effects of prenatal opioid exposure on the early development of fine motor and communication skills. Similar findings were obtained for prescribed and illicit opioid use, underscoring developmental risks of both MAT and untreated substance use. Exploratory analyses investigating type and timing of MAT suggest directions for future research.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Infant development; Medication-assisted treatment; Polysubstance use; Prenatal opioid exposure; Timeline follow-back interview

Mesh:

Year:  2021        PMID: 34116198      PMCID: PMC8277730          DOI: 10.1016/j.ntt.2021.107000

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   4.071


  36 in total

1.  Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome.

Authors:  Adam J Czynski; Jonathan M Davis; Lynne M Dansereau; Barbara Engelhardt; Peter Marro; Debra L Bogen; Mark L Hudak; Jeffrey Shenberger; Elisha M Wachman; Erica L Oliveira; Barry M Lester
Journal:  J Pediatr       Date:  2020-01-24       Impact factor: 4.406

Review 2.  Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development.

Authors:  Carolien Konijnenberg; Annika Melinder
Journal:  Child Neuropsychol       Date:  2011-06-24       Impact factor: 2.500

Review 3.  Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.

Authors:  Sarah C Akerman; Mary F Brunette; Alan I Green; Daisy J Goodman; Heather B Blunt; Sarah H Heil
Journal:  J Subst Abuse Treat       Date:  2014-12-22

4.  Neurodevelopmental Outcomes of Children Born to Opioid-Dependent Mothers: A Systematic Review and Meta-Analysis.

Authors:  Samantha J Lee; Samudragupta Bora; Nicola C Austin; Anneliese Westerman; Jacqueline M T Henderson
Journal:  Acad Pediatr       Date:  2019-11-14       Impact factor: 3.107

5.  Changes in smoking patterns during pregnancy.

Authors:  Rina D Eiden; Gregory G Homish; Craig R Colder; Pamela Schuetze; Teresa R Gray; Marilyn A Huestis
Journal:  Subst Use Misuse       Date:  2013-04-12       Impact factor: 2.164

6.  Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.

Authors:  Hendrée E Jones; Erin Dengler; Anna Garrison; Kevin E O'Grady; Carl Seashore; Evette Horton; Kim Andringa; Lauren M Jansson; John Thorp
Journal:  Drug Alcohol Depend       Date:  2013-11-16       Impact factor: 4.492

7.  Development after prenatal exposure to cocaine, heroin and methadone.

Authors:  A L van Baar; S Soepatmi; W B Gunning; G W Akkerhuis
Journal:  Acta Paediatr Suppl       Date:  1994-11

8.  A longitudinal study of offspring born to methadone-maintained women. III. Effects of multiple risk factors on development at 4, 8, and 12 months.

Authors:  J Marcus; S L Hans; R J Jeremy
Journal:  Am J Drug Alcohol Abuse       Date:  1984       Impact factor: 3.829

9.  Transgenerational actions of environmental compounds on reproductive disease and identification of epigenetic biomarkers of ancestral exposures.

Authors:  Mohan Manikkam; Carlos Guerrero-Bosagna; Rebecca Tracey; Md M Haque; Michael K Skinner
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

Review 10.  Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities.

Authors:  Elisabeth Conradt; Tess Flannery; Judy L Aschner; Robert D Annett; Lisa A Croen; Cristiane S Duarte; Alexander M Friedman; Constance Guille; Monique M Hedderson; Julie A Hofheimer; Miranda R Jones; Christine Ladd-Acosta; Monica McGrath; Angela Moreland; Jenae M Neiderhiser; Ruby H N Nguyen; Jonathan Posner; Judith L Ross; David A Savitz; Steven J Ondersma; Barry M Lester
Journal:  Pediatrics       Date:  2019-09       Impact factor: 9.703

View more
  2 in total

1.  Stressful life events and prescription opioid use during pregnancy: findings from the 2019 pregnancy risk assessment monitoring system.

Authors:  Alexander Testa; Allison D Crawford; Dylan B Jackson; Alison Gemmill
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-08-10       Impact factor: 4.519

2.  Alterations in Excitatory and Inhibitory Synaptic Development Within the Mesolimbic Dopamine Pathway in a Mouse Model of Prenatal Drug Exposure.

Authors:  Taylor Boggess; James C Williamson; Ethan B Niebergall; Hannah Sexton; Anna Mazur; Richard D Egleton; Lawrence M Grover; W Christopher Risher
Journal:  Front Pediatr       Date:  2021-12-13       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.